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The OBO Foundry: coordinated evolution of 
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Scheuermann14, Nigam Shah15, Patricia L Whetzel16 & Suzanna Lewis10
The value of any kind of data is greatly enhanced when it exists 
in a form that allows it to be integrated with other data. One 
approach to integration is through the annotation of multiple 
bodies of data using common controlled vocabularies or 
‘ontologies’. Unfortunately, the very success of this approach 
has led to a proliferation of ontologies, which itself creates 
obstacles to integration. The Open Biomedical Ontologies (OBO) 
consortium is pursuing a strategy to overcome this problem. 
Existing OBO ontologies, including the Gene Ontology, are 
undergoing coordinated reform, and new ontologies are being 
created on the basis of an evolving set of shared principles 
governing ontology development. The result is an expanding 
family of ontologies designed to be interoperable and logically 
well formed and to incorporate accurate representations of 
biological reality. We describe this OBO Foundry initiative and 
provide guidelines for those who might wish to become involved.
In the search for what is biologically and clinically significant in the 
swarms of data being generated by today’s high-throughput technolo-
gies, a common strategy involves the creation and analysis of ‘anno-
tations’ linking primary data to expressions in controlled, structured 
vocabularies, thereby making the data available to search and to algo-
rithmic processing1. The most successful such endeavor, measured both 
by numbers of users and by reach across species and granularities, is 
the Gene Ontology (GO)2. There exist over 11 million annotations 
relating gene products described in the UniProt, Ensembl and other 
databases to terms in the GO3, of which half a million have been manu-
ally verified by specialist curators in different model-organism com-
munities on the basis of the analysis of experimental results reported 
in 52,000 scientific journal articles (http://www.ebi.ac.uk/GOA/). Data 
related to some 180,000 genes have been manually annotated in this way, 
an endeavor now being refined and systematized within the Reference 
Genome Project (US National Institutes of Health National Human 
Genome Research Institute grant 2P41HG002273-07), which will pro-
vide comprehensive GO annotations for both the human genome and 
a representative set of model-organism genomes in support of research 
on the primary molecular systems affecting human health.
From retrospective mapping to prospective standardization
The domain of molecular biology is marked by the availability of large 
amounts of well defined data that can be used without restriction as 
inputs to algorithmic processing. In the clinical domain, by contrast, 
only limited amounts of data are available for research purposes, 
and these still consist overwhelmingly of natural language text. Even 
where more systematic clinical data are available, the use of local cod-
ing schemes means that these data do not cumulate in ways useful to 
research4. One approach to solving this problem is the Unified Medical 
Language System (UMLS)5, a compendium of some 100 source vocabu-
laries combined through a process of retrospective mapping based on 
the identification of synonymy relations between constituent terms. The 
UMLS has yielded very useful results for applications such as indexing 
and retrieval of documents. But because the separate vocabularies have 
no common architecture6,7, UMLS mappings do not meld their terms 
together into any single system8.
Increasingly, therefore, the need is being recognized for strategies of 
prospective standardization designed to bring about the progressive 
improvement and reciprocal alignment of the frameworks employed 
for the management, description and publication of biomedical data. 
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Two conspicuous products of this trend are the US National Cancer 
Institute’s Cancer Biomedical Informatics Grid (caBIG) project9 and 
HL7’s Reference Information Model (RIM) (http://hl7.org). caBIG seeks 
to integrate all cancer research data in a common cyberinfrastructure 
by standardizing the ways in which such data are acquired, formatted, 
processed and stored. The HL7 RIM, similarly, offers a standard for the 
exchange, management and integration of all information relevant to 
healthcare, from clinical genomics to hospital billing. However, because 
both caBIG and HL7 focus on the meta-level question of how data and 
information should be represented in computer and messaging systems, 
it can be argued that they fail to do justice to the object-level question of 
how best to represent the proteins, organisms, diseases or drug interac-
tions that are of primary interest in biomedical research7,10.
A collaborative experiment in ontology development
In 2001, Ashburner and Lewis initiated a strategy to address this object-
level question by creating OBO, an umbrella body for the developers 
of life-science ontologies. OBO applies the key principles underlying 
the success of the GO, namely, that ontologies be open, orthogonal, 
instantiated in a well-specified syntax and designed to share a com-
mon space of identifiers11. Ontologies must be open in the sense that 
they and the bodies of data described in their terms should be available 
for use without any constraint or license and so be applicable to new 
purposes without restriction. They are also receptive to modification 
as a result of community debate. They must be orthogonal to ensure 
additivity of annotations and to bring the benefits of modular develop-
ment. They must be syntactically in good order to support algorithmic 
processing. And they must employ a common system of identifiers to 
enable backward compatibility with legacy annotations as the ontolo-
gies evolve.
OBO now comprises over 60 ontologies, and its role as an ontol-
ogy information resource is supported by the NIH Roadmap National 
Center for Biomedical Ontology (NCBO) through its BioPortal12. At the 
same time, the developers of a subset of OBO ontologies have initiated 
the OBO Foundry, a collaborative experiment based on the voluntary 
acceptance by its participants of an evolving set of principles (available at 
http://obofoundry.org) that extend those of the original OBO by requir-
ing in addition that ontologies (i) be developed in a collaborative effort, 
(ii) use common relations that are unambiguously defined, (iii) provide 
procedures for user feedback and for identifying successive versions and 
(iv) have a clearly bounded subject-matter (so that an ontology devoted 
to cell components, for example, should not include terms like ‘data-
base’ or ‘integer’). A graphical representation of the coverage of the initial 
Foundry ontologies is provided in Table 1.
Progress thus far
Since the OBO Foundry was established, ontologies such as the GO and 
the Foundational Model of Anatomy (FMA)13 have been reformed and 
new ontologies created on the basis of its principles14–16. Perhaps most 
importantly, ontologies have been laid to rest. Before the OBO Foundry 
there existed at least four cell-type ontologies: one from Bard, Rhee and 
Ashburner17, another from Kelso et al.18, a third implicit within the GO 
and the fourth a subontology within the FMA. The first three now form 
a single cell-type ontology (CL)19, which is itself being integrated with 
the cell-type representations contained within the FMA.
The Foundry initiative also serves to align ontology development 
efforts carried out by separate communities, for example in research on 
different model organisms. The potential of such research to yield results 
valuable for the understanding of human disease rests on our ability 
to make reliable cross-species comparisons. Because so much model- 
organism data is localized to anatomical structures, drawing inferences 
on the basis of such comparisons has been hampered by the lack of coor-
dination in anatomy ontology development among different communi-
ties. Some ontologies represent structure, others represent function, yet 
others represent stages of development, and some draw on combinations 
of these, in ways that close off opportunities for automatic reasoning. 
The Foundry has created a roadmap for the incremental resolution of 
this problem through the initiation of the Common Anatomy Reference 
Ontology (CARO)14, which is providing guidelines both for model-
organism communities with legacy anatomy ontologies who wish to initi-
ate reforms in the direction of compatibility and for communities who 
wish to build new ontologies from scratch. CARO is based on the top-
level types of the FMA and is serving as a template for the creation of the 
Fish Multi-Species, Ixodidae and Argasidae (tick), mosquito and Xenopus 
anatomy ontologies, and also as basis for reforms of the Drosophila and 
zebrafish anatomy ontologies19.
The Ontology for Biomedical Investigations (OBI) addresses the 
need for controlled vocabularies to support integration of experimen-
tal data, a need originally identified in the transcriptomics domain by 
the Microarray Gene Expression Data Society (MGED), which devel-
oped the MGED Ontology20 as an annotation resource for microarray 
data. In response to the recognition of convergent needs in areas such 
as protein and metabolite characterization, this effort was broadened 
to become what was initially known as FuGO (Functional Genomics 
Investigation Ontology)21. FuGO was further expanded in 2006 to 
include clinical and epidemiological research, biomedical imaging 
and a variety of further experimentation domains to become what is 
today OBI, an ontology designed to serve the coordinated representa-
tion of designs, protocols, instrumentation, materials, processes, data 
Table 1  Coverage of initial Foundry ontologies
Continuant Occurrent
Independent Dependent
Granularity
Organ and
organism
Organism
(NCBI taxonomy or 
similar)
Anatomical entity
(FMA, CARO)
Organ function
(Physiology ontology, to be 
determined)
Phenotypic quality (PATO)
Organism-level process (GO)
Cell and cellular  
component
Cell (CL, FMA)
Cellular component 
(FMA,GO)
Cellular function (GO) Cellular process (GO)
Molecule Molecule (ChEBI, SO, RnaO, PRO) Molecular function (GO) Molecular process (GO)
Down the left column is the granularities (spatial scales) of the entities represented in the ontologies; along the top is a division corresponding to the ways these entities exist in time47. 
‘Continuants’ endure through time. ‘Occurrents’ (processes) unfold through time in successive stages. Continuants are divided into physical things, on the one hand, and qualities and func-
tions, on the other. The latter are dependent continuants: a quality such as the shape of a fly’s wing depends for its existence on, and endures through time in tandem with, the wing that is 
its bearer; a function, such as the function of an enzyme to catalyze reactions of a certain type, similarly endures through time in tandem with the enzyme itself and exists even when it is 
not being exercised in any instance of that reaction. NCBI, US National Center for Biotechnology Information; CL, Cell Ontology; SO, Sequence Ontology; RnaO, RNA Ontology; PRO, Protein 
Ontology.
PERSPECTIVE
©
2
0
0
7
 
N
a
t
u
r
e
 
P
u
b
l
i
s
h
i
n
g
 
G
r
o
u
p
 
 
h
t
t
p
:
/
/
w
w
w
.
n
a
t
u
r
e
.
c
o
m
/
n
a
t
u
r
e
b
i
o
t
e
c
h
n
o
l
o
g
yNATURE BIOTECHNOLOGY  VOLUME 25   NUMBER 11   NOVEMBER 2007  1253
and types of analysis in all areas of biological and biomedical investiga-
tion. Twenty-five groups are now involved in building OBI (http://obi.
sf.net/community), and the Foundry discipline has proven essential to 
its distributed development.
Unlike most OBO ontologies, which use the OBO file format and the 
associated OBO-Edit software favored by model-organism and other 
biologist communities, OBI uses the OWL-DL Web Ontology Language. 
The need to make OWL and OBO ontologies interoperable has sparked 
the creation of bidirectional OBO–OWL conversion tools22 that inte-
grate data annotated in terms of the GO and other OBO ontologies 
with the bodies of data coming onstream within the framework of the 
Semantic Web23 an influential initiative to exploit OWL ontologies to 
encode knowledge in distributed computer systems24.
Models of good practice
Each Foundry ontology forms a graph-theoretic structure, with terms 
connected by edges representing relations such as ‘is_a’ or ‘part_of’ in 
assertions such as ‘serotonin is_a biogenic amine’ or ‘cytokinesis part_of 
cell proliferation’. Because relations in OBO ontologies were initially used 
in inconsistent ways25, the OBO Relation Ontology (RO)26 was developed 
to provide guidelines to ontology builders in the consistent formulation 
of relational assertions. These guidelines are already proving useful—for 
example, in the representation of anatomical change27 and in linking 
diverse image collections to phylogenetic datasets28.
Other areas in which the Foundry is providing guidelines include nam-
ing conventions29 and pathway representations30. The model of good 
practice in the formulation of definitions is the FMA13, a representation 
of types of anatomical entities built around two backbone hierarchies of 
‘is_a’ and ‘part_of’ relations. The FMA imposes a rule whereby all defini-
tions take the genus-species form:
an A = def. a B that C’s where B is the ‘is_a’ parent of A, and C are 
the differentia marking out that subfamily of Bs which are also As. For 
example,
cell = def. an anatomical structure that has as its boundary the external 
surface of a maximally connected plasma membrane
plasma membrane = def. a cell component that has as its parts a maxi-
mal phospholipids bilayer in which instances of two or more types of 
protein are embedded.
Anchoring definitions in the ‘is_a’ hierarchy in this way diminishes 
the role of opinion in determining where terms should be placed in the 
hierarchy, thereby fostering consistency both within and between ontolo-
gies and helping to prevent common errors6,7,26.
To maximize cross-ontology coordination, compound terms should 
be built as far as possible out of constituent terms drawn from Foundry 
ontologies linked using relational expressions from the RO31. This 
methodology of cross-products is being applied, in one of the biological 
projects driving the NCBO, to the annotation of Drosophila, zebrafish 
and human alleles for genes implicated in disease12,32. Specialist cura-
tors associate these alleles with phenotype descriptions formulated using 
terms drawn from more than one OBO Foundry ontology—for example, 
composing the Phenotypic Quality Ontology (PATO) term ‘increased 
concentration’ with the FMA term ‘blood’ and the ChEBI term ‘glucose’ 
to represent increased blood glucose phenotypes. Such creation of terms 
through explicit composition avoids the bottlenecks created where, as 
for example in the Mammalian Phenotype Ontology, each new term 
must be approved for inclusion in the ontology before it can be used 
in annotations. But the approach will work only if the resultant terms 
are unambiguous, and here the Foundry helps provide the necessary 
rigor. The orthogonality principle helps to reduce the need for arbi-
trary decisions between equivalent-seeming terms drawn from different 
ontologies, the PATO phenotypic-quality ontology provides templates 
for term formation, and the RO provides formally coherent glue for 
combination33.
The current scope of the OBO Foundry initiative is summarized in 
Table 2. Foundry ontologies are created and maintained by biologists 
with a thorough knowledge of the underlying science. Where domain 
experts jointly control ontology, data, and annotations (as in the case 
of the GO/Uniprot collaboration), all three can be curated in tandem 
in a way that provides a reality check at each stage of the process34. 
As results of experiments are described in annotations, this leads to 
extensions or corrections of the ontology, which in turn lead to better 
annotation35. The results of the Foundry’s work can then be applied 
by external groups as benchmarks—for example, to help identify genes 
mutated at significant frequencies in human cancers36 or to identify 
cellular components involved in antigen processing37 or, in general, to 
refine otherwise noisy results of text- and data-mining38–41.
The OBO Foundry applied
Neurophysiology. A demonstration of the utility of the Foundry 
methodology is provided by ongoing work to create the NeuronDB 
database  within  the  Senselab  project  (http://senselab.med.yale.
edu/). NeuronDB encompasses three types of neuronal property: 
voltage-gated conductances, neurotransmitters and neurotransmitter 
receptors. An initial representation of neurotransmitters defined an 
‘is_a’ hierarchy with classes such as ‘neurotransmitter receptor’ and 
subclasses such as ‘GABA receptor’.  In this initial ontology, receptors 
were not defined, and strictly speaking one would not have known, 
for example, whether a receptor was a protein or a protein complex. 
The Foundry provided a set of principles and at least one task that 
may be evaluated in making such choices: namely, the scope of each 
ontology should be clearly bounded and (by orthogonality) no term 
should appear in more than one ontology. Reviewing the existing 
ontologies, we found that the GO Molecular Function (GO MF) 
ontology already had classes such as ‘receptor activity’ (GO:0004872) 
and a number of subclasses that described receptor activities that 
were referred to in NeuronDB.
We reviewed one hundred thirty resultant receptor classes. Where 
they existed, we reused MF classes; where they did not, we created 
subclasses of existing MF classes and submitted the results to GO for 
future inclusion. Arranging NeuronDB to interoperate transparently 
with GO provided the further benefit that we can now take advantage 
of GO annotations to find the proteins that correspond to the recep-
tor classes by searching annotations to the MF terms. This is a model 
for how small ontology builders can constructively contribute to the 
growth of shared resources while simultaneously benefiting users of 
their own ontologies.
Neuroanatomy. In support of research on neurodegenerative and 
neurological disease within the Biomedical Informatics Research 
Network (BIRN)42, the BIRN Ontology Task Force is applying the 
Foundry principles to formally represent several large domains, 
including (i) neuroanatomy43, where annotations must capture not 
only the structural systems of parthood and topological connection 
but also cytoarchitectural parcellations such as the CA1, CA2 and CA3 
regions of the hippocampus, (ii) functional systems, such as the basal 
ganglion circuits for motor planning and motor memory and (iii) 
neurochemistry (for example, of brainstem monoamine nuclei). The 
members of the BIRN Ontology Task Force see the Foundry as provid-
ing a framework within which these distinct axes can be algorithmically 
combined, and they are incorporating the results into BIRN’s neuro-
image atlasing project and using them to integrate spatially mapped 
microarray expression data with mouse imaging results.
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The  Minimum  Information  for  Biological  and  Biomedical 
Investigations (MIBBI). This initiative represents the first new stan-
dards effort that takes OBO and the OBO Foundry as its role model44. 
MIBBI provides information resources to promote the consolidation 
of the many prescriptive checklists that specify core metadata items 
to be included when reporting results in a variety of experimenta-
tion domains45. The proliferation of such ‘minimum information’ 
checklists has made it increasingly difficult to obtain an overview of 
existing specifications, unnecessarily duplicating efforts and creating 
problems when third parties try to use described information. The 
MIBBI Portal operates analogously to OBO and the NBCO Bioportal 
as an open information resource for all initiatives addressing these 
problems; the MIBBI Foundry fosters collaborative development and 
integration of checklists into orthogonal modules46.
How to join
Like OBO, the OBO Foundry is an open community. Any individual 
or group working in the domain of biomedicine wishing to join the 
initiative is encouraged to do so, and all discussion forums (listed 
at http://obofoundry.org) are open to all interested parties without 
restriction. The recommended first step is to join one or more mailing 
lists in salient areas as a way to become familiar with the Foundry’s 
collaborative methodology and identify members with overlapping 
expertise. Those with new ontology resources are invited to submit 
them for informal consideration by existing members; this will be fol-
lowed by a period in which compliance with the Foundry principles is 
addressed, especially as concerns potential conflicts in areas of overlap. 
Membership in the Foundry initiative then flows from a commitment 
to incremental implementation of these principles as they evolve over 
time, with the Foundry coordinators (currently Ashburner, Lewis, 
Mungall and Smith) serving as analogs of journal editors, whereby 
the division of labor that results from orthogonality helps ensure that 
development decisions are made by the authors of single ontologies. 
By joining the initiative, the authors of an ontology commit to work-
ing with other members to ensure that, for any particular domain, 
there is convergence on a single ontology. Criticism, too, is welcomed: 
the Foundry is an attempt to apply the scientific method to the task of 
ontology development, and thus it accepts that no resource will ever 
exist in a form that cannot be further improved.
Our long-term goal is that the data generated through biomedical 
research should form a single, consistent, cumulatively expanding 
and algorithmically tractable whole. Our efforts to realize this goal, 
which are still very much in the proving stage, reflect an attempt to 
walk the line between the flexibility that is indispensable to scientific 
advance and the institution of principles that is indispensable to suc-
cessful coordination.
Table 2  OBO Foundry ontologies (as of April 2007)
Ontology Scope URL Custodians
Mature ontologies undergoing incremental reform
Cell Ontology (CL) Cell types from prokaryotic to mammalian
http://obofoundry.org/cgi-bin/detail.
cgi?cell
Michael Ashburner, Jonathan Bard, 
Oliver Hofmann, Sue Rhee
Gene Ontology (GO) Attributes of gene products in all organisms http://www.geneontology.org Gene Ontology Consortium
Foundational Model of Anatomy 
(FMA)
Structure of the mammalian and in  
particular the human body
http://fma.biostr.washington.edu J.L.V. Mejino, Jr., Cornelius Rosse
Zebrafish Anatomical Ontology 
(ZAO)
Anatomical structures in Danio rerio
http://zfin.org/zf_info/anatomy/dict/sum.
html
Melissa Haendel, Monte Westerfield
Mature ontologies still in need of thorough review
Chemical Entities of Biological 
Interest (ChEBI)
Molecular entities which are products of 
nature or synthetic products used to inter-
vene in the processes of living organisms
http://www.ebi.ac.uk/chebi Paula Dematos, Rafael Alcantara
Disease Ontology (DO) Types of human disease http://diseaseontology.sf.net Rex Chisholm
Plant Ontology (PO)
Flowering plant structure, growth and  
development stages
http://plantontology.org Plant Ontology Consortium
Sequence Ontology (SO)
Features and properties of nucleic acid 
sequences
http://www.sequenceontology.org Karen Eilbeck
Ontologies for which early versions exist
Ontology for Clinical  
Investigations (OCI)
Clinical trials and related clinical studies
http://www.bioontology.org/wiki/index.
php/CTO:Main_Page
OCI Working Group
Common Anatomy Reference 
Ontology (CARO)
Anatomical structures in all organisms
http://obofoundry.org/cgi-bin/detail.
cgi?caro
Fabian Neuhaus, Melissa Haendel, 
David Sutherland
Environment Ontology
Habitats and associated spatial regions and 
sites
http://www.obofoundry.org/cgi-bin/detail.
cgi?id=envo
Norman Morrison, Dawn Field
Ontology for Biomedical 
Investigations (OBI)
Design, protocol, instrumentation and  
analysis applied in biomedical  
investigations
http://obi.sf.net OBI Working Group
Phenotypic Quality Ontology 
(PATO)
Qualities of biomedical entities http://www.phenotypeontology.org
Michael Ashburner, Suzanna Lewis, 
Georgios Gkoutos
Protein Ontology (PRO)
Protein types and modifications classified 
on the basis of evolutionary relationships
http://pir.georgetown.edu/pro Protein Ontology Consortium
Relation Ontology (RO) Relations in biomedical ontologies http://obofoundry.org/ro Barry Smith, Chris Mungall
RNA Ontology (RnaO)
RNA three-dimensional structures, 
sequence alignments, and interactions
http://roc.bgsu.edu/ RNA Ontology Consortium
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